Advertisement


Eric Jonasch, MD, on Kidney Cancer: A Year in Review

NCCN Annual Conference 2019

Advertisement

Eric Jonasch, MD, of The University of Texas MD Anderson Cancer Center, discusses major findings over the past 12 months in kidney cancer, including combination immunotherapies and trends in surgical oncology.



Related Videos

Supportive Care

Michelle B. Riba, MD, on Screening for Distress in Cancer: Implementing the Standard of Care

Michelle B. Riba, MD, of the University of Michigan Rogel Cancer Center, discusses the prevalence of distress in patients with cancer, the need for a quick and simple screening method to identify patients with distress, and strategies for improving integration of psychosocial care into routine cancer care.

Prostate Cancer

James L. Mohler, MD, on Managing Prostate Cancer: NCCN Guidelines Updates

James L. Mohler, MD, of the Roswell Park Comprehensive Cancer Center, discusses updated recommendations in prostate cancer: more specificity for family history and genomic sequencing, as well as the evolving uses of androgen-deprivation therapy.

Breast Cancer

William J. Gradishar, MD, on HR-Positive, HER2-Negative Advanced Breast Cancer: NCCN Guidelines Updates

William J. Gradishar, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses evidence-based first-line treatment options for patients with advanced hormone receptor–positive, HER2-negative breast cancer and toxicities associated with the various therapeutic options.

Pancreatic Cancer

Margaret A. Tempero, MD, on Pancreatic Cancer: NCCN Guidelines Updates

Margaret A. Tempero, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, discusses new adjuvant therapy options for patients with pancreatic cancer, and germline testing, including testing for microsatellite instability/mismatch repair genes as well as molecular analysis of all tumors.

Breast Cancer

Melinda L. Telli, MD, on NCCN Guidelines Updates for HR-Positive, HER2-Negative Early-Stage Breast Cancer

Melinda L. Telli, MD, of the Stanford Cancer Institute, discusses the various systemic therapies for patients with early-stage hormone receptor–positive, HER2-negative disease.

Advertisement

Advertisement




Advertisement